A research group of the Zurich University of the Arts (ZHdK) has developed a foldable surgical tool, 3Fold, for pacemaker implantations. 3Fold is the result of the bio-synthetic material, Hylomate, developed by the Technopark Zurich-based Hylomorph AG.

Hylomorph AG has closed an oversubscribed Series B2 financing round worth CHF 4.5 million (USD 5.1 million) with leading healthcare investors. Hylomorph was previously accelerating at Wyss Zurich.

CUTISS AG, hemotune AG, HYLOMORPH AG and Nanoflex Robotics AG receive funding within the framework of the Swiss Accelerator

HYLOMORPH AG, a Wyss Zurich alumni and rapidly growing clinical-stage medtech startup with a history of national and international recognition, completed a CHF 5.2 million Series-B financing round. At the same time, the company attracted CHF 0.9 million in new non-dilutive funding.

Hylomorph has announced the positive evaluation by an independent Data Safety Monitoring Board of the clinical safety for their product Hylomate.

HYLOMORPH reaches a significant milestone with the conduction of a first-in-man clinical trial that marks the successful completion of its incubation period at Wyss Zurich.

HYLOMORPH has won first place at the 2019 EHRA Innovations Awards, which took place at the European Heart Rhythm Association (EHRA) conference in Lisbon.

HYLOMORPH, an ETH Zurich spin-off and Medtech startup, closes its Series A financing round with CHF 3.2 million.

The Project Co-Leader of the Wyss Zurich project HYLOMORPH, Simone Bottan, raised CHF130,000 in start capital, the maximum funding granted by Venture Kick.